|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||151.19 - 155.12|
|52 Week Range||136.54 - 164.17|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.05%|
It is often said that large-caps, many of which are multi-national firms generating significant portions of their revenue overseas, benefit from a weak dollar while smaller companies, due to their domestic ...
TalkTalk (TALK.L) raised 200 million pounds from investors on Thursday to help fund a plan to connect three million British homes and businesses with ultrafast broadband and keep it competitive with bigger rivals. The British firm said it had provisionally agreed to set up an independent company with M&G Prudential to build the network, with a combined potential equity investment of up to 500 million pounds and borrowing of around 1 billion pounds. "TalkTalk's announcement is a major rolling of the dice to turn around the fortunes of a company dogged by profits warnings and underperformance versus larger peers," said Henry Croft, research analyst at Accendo Markets.
On January 30, 2018, Varian Medical Systems (VAR) announced that it had signed an agreement to acquire Australia-based Sirtex Medical Limited for 28 Australian dollars per share in cash, amounting to a total purchase price of $1.3 billion. As per the deal, Varian will acquire all outstanding shares of Sirtex, which is listed on the Australian Securities Exchange. Sirtex is a global life sciences company that’s focused on interventional oncology therapies.
Hopes for Trump's tax reforms, abating North Korea fears, lower-than-expected damage from Hurricane Irma and record stock market highs rekindled the love for U.S. equity ETFs last week.
It may be surprising to hear that in a year in which ETFs are shattering all sorts of records with regard to the amount of money they are taking in, the world's largest exchange-traded fund isn't participating in the bonanza. That's right; the SPDR S&P 500 ETF Trust (SPY), the $242 billion behemoth, has actually had net outflows this year to the tune of $4.2 billion.
In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.
This trial demonstrated the efficacy and safety of JAZZ's JZP-110 in both the MWT and sleep latency tests at all dosages at the end of weeks 4 and 12.
In 2Q17, Dentsply Sirona’s (XRAY) Dental and Healthcare Consumables business contributed ~56% to the company’s total revenues and registered sales of ~$554 million.
In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly ...
To diversify its focus beyond aortic structural heart conditions, Edwards Lifesciences (EW) acquired CardiAQ Valve Technologies in August 2015.
In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.
In 2Q17, Edwards Lifesciences’ (EW) Transcatheter Heart Valve Therapy segment reported revenues close to $316 million, which represents year-over-year growth of ~28%.
What's been unusual about this year's market ascent is not how much stocks have risen. A gain of 12% for the SPDR S&P 500 ETF (SPY) through seven months of the year, while impressive, is well within historical norms. Rather, it's been the consistency and uniformity of the rally that has caught everyone off guard. In the ETF world, an investor could almost throw a dart and come up with gains. Everything from mega-caps to large-caps to midcaps to small-caps is up.
Taking advantage of one of the greatest benefits of ETFs—transparency—can lead to some surprising discoveries. Case in point: the world of small-cap ETFs. We’ve discovered that while a number of ETFs call themselves “small-caps,” they really don't have that much small-cap exposure. And that matters, because a fund that isn’t exactly small-cap is going to deliver different risks and different returns than a pure small-cap strategy. Clarifying Terms
In 1Q17, around 12.1 million members were enrolled in Centene's (CNC) various healthcare plans, which is a year-over-year (or YoY) rise of around 600,000 beneficiaries.
With around 50.0% of hospitals being served by Quest Diagnostics (DGX), the company has become a leading player in the fragmented US laboratory market.
Broadly speaking, exchange-traded funds have been on a torrid pace of asset gathering through the first quarter, but there have recently been some signs of departures from large-cap equity funds. Data ...